BMY Stock Summary and Trading Ideas (Bristol-Myers Squibb Company | NYSE:BMY)

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Bristol-Myers Squibb Company trades on the NYSE stock market under the symbol BMY.

As of December 10, 2025, BMY stock price climbed to $51.21 with 10,329,660 million shares trading.

BMY has a beta of 0.39, meaning it tends to be less sensitive to market movements. BMY has a correlation of 0.06 to the broad based SPY ETF.

BMY has a market cap of $104.20 billion. This is considered a Large Cap stock.

Last quarter Bristol-Myers Squibb Company reported $12 billion in Revenue and $1.63 earnings per share. This beat revenue expectation by $410 million and exceeded earnings estimates by $.12.

In the last 3 years, BMY traded as high as $79.36 and as low as $39.35.

The top ETF exchange traded funds that BMY belongs to (by Net Assets): SCHD, VTI, VOO, IVV, SPY.

BMY has underperformed the market in the last year with a return of -8.6%, while SPY returned +14.9%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in BMY shares. However, BMY has outperformed the market in the last 3 month and 2 week periods, returning +9.7% and +4.4%, while SPY returned +6.0% and +1.9%, respectively. This indicates BMY has been having a stronger performance recently.

BMY support price is $49.59 and resistance is $51.71 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BMY shares will trade within this expected range on the day.